Mohammad Azab - Dec 19, 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Sherry Aulin, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Dec 19, 2023
Transactions value $
$42,552
Form type
4
Date filed
12/20/2023, 05:04 PM
Previous filing
Jun 23, 2023
Next filing
Jan 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $8.11K +823 +1.18% $9.85 70.7K Dec 19, 2023 Direct F1, F2
transaction XENE Common Shares Options Exercise $34.4K +3.5K +4.94% $9.85 74.2K Dec 19, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -823 -100% $0.00* 0 Dec 19, 2023 Common Shares 823 $9.85 Direct F2
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3.5K -100% $0.00* 0 Dec 19, 2023 Common Shares 3.5K $9.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023.
F2 The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.